The UK and US have forged a key commercial pact that will keep zero import taxes on British drug exports entering the US market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to raise expenditure on drugs through the public health system. This pledge ensures that import taxes on these crucial goods will remain at nothing for a timeframe of the next three years.
This agreement comes after earlier threats to hike duties on branded drug products, with increases floated reaching 100%.
"This arrangement with the United Kingdom bolsters the worldwide climate for new treatments and establishes much-needed fairness to U.S.–U.K. drug exports," a release said.
Trade Impact
Medicines are one of the UK's biggest exports to the US, which is clearly the largest market for major British pharmaceutical firms.
Export figures reveal that in the 12 months leading up to last September, the UK exported pharmaceutical products worth billions to the US. This amount represented 17.4% of all goods exports in that span.
"This deal secures jobs, stimulates capital expenditure and facilitates the UK to become a worldwide center for life sciences," a minister commented.
Specific NHS Changes
The agreement involves several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new treatments to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to increase overall NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount manufacturers must return to the NHS to control costs will be restricted at 15%. In the past, rebates exceeded twenty percent.
Recent Tensions
The pact follows a protracted dispute between the drug companies and the ministers over drug pricing and NHS adoption.
The disagreement were heightened by arguments that US patients were paying a premium for the identical medicines than consumers in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been delayed or scrapped, while major funding commitments have been directed toward US facilities.
A senior figure acknowledged that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the last ten years.
